Stay updated on FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial

Sign up to get notified when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The 403 error message, breadcrumb labels, and NIH transition announcement are no longer displayed. The page is left with the site navigation and footer but little visible main content.
    Difference
    3%
    Check dated 2026-11-08T06:16:56.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision indicator changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-01T04:52:56.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A site-wide NIH notice about terminology changes during a transition appears above the 403 error message.
    Difference
    1%
    Check dated 2026-10-25T06:47:24.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page’s footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T06:34:06.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T08:19:12.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    A 403 Forbidden page is displayed for the study record, replacing the normal content and navigation; the study details are now inaccessible due to access restrictions.
    Difference
    20%
    Check dated 2026-09-20T03:18:34.000Z thumbnail image

Stay in the know with updates to FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.